Literature DB >> 19654543

Uric acid: a novel mediator and marker of risk in chronic kidney disease?

Daniel I Feig1.   

Abstract

PURPOSE OF REVIEW: To assess the current data suggesting that uric acid-lowering therapy may be useful in the prevention or mitigation of chronic kidney disease (CKD). RECENT
FINDINGS: Eleven observational studies assessing the potential role of serum uric acid in the prevalence and progression of CKD have been published in the past 2 years. Seven suggest an association, whereas four do not. Recent experimental models and clinical trials have mechanistically linked serum uric acid and hypertension, an established risk factor for CKD.
SUMMARY: Elevated serum uric acid is a marker for decreased renal function, may have a mechanistic role in the incidence and progression of renal functional decline and likely has a causal role in hypertension and vascular disease. Clinical trials are needed to determine whether uric acid-lowering therapy will be effective in preventing CKD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654543      PMCID: PMC2885828          DOI: 10.1097/MNH.0b013e328330d9d0

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  29 in total

1.  The kidney in gout.

Authors:  J H TALBOTT; K L TERPLAN
Journal:  Medicine (Baltimore)       Date:  1960-12       Impact factor: 1.889

2.  Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.

Authors:  Yui-Pong Siu; Kay-Tai Leung; Matthew Ka-Hang Tong; Tze-Hoi Kwan
Journal:  Am J Kidney Dis       Date:  2006-01       Impact factor: 8.860

3.  Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.

Authors:  M Mazzali; J Hughes; Y G Kim; J A Jefferson; D H Kang; K L Gordon; H Y Lan; S Kivlighn; R J Johnson
Journal:  Hypertension       Date:  2001-11       Impact factor: 10.190

Review 4.  Allopurinol hypersensitivity syndrome: a review.

Authors:  F Arellano; J A Sacristán
Journal:  Ann Pharmacother       Date:  1993-03       Impact factor: 3.154

5.  Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.

Authors:  Marilda Mazzali; John Kanellis; Lin Han; Lili Feng; Yi-Yang Xia; Qiang Chen; Duk-Hee Kang; Katherine L Gordon; Susumu Watanabe; Takahiko Nakagawa; Hui Y Lan; Richard J Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2002-06

Review 6.  Uric acid elimination in the urine. Pathophysiological implications.

Authors:  Martino Marangella
Journal:  Contrib Nephrol       Date:  2005       Impact factor: 1.580

Review 7.  Uric acid and hypertension.

Authors:  Daniel I Feig; Duk-Hee Kang; Takahiko Nakagawa; Marilda Mazzali; Richard J Johnson
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

8.  Hyperuricemia and urate nephropathy in urate oxidase-deficient mice.

Authors:  X Wu; M Wakamiya; S Vaishnav; R Geske; C Montgomery; P Jones; A Bradley; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

9.  Uric acid is associated with the rate of residual renal function decline in peritoneal dialysis patients.

Authors:  Jung Tak Park; Dong Ki Kim; Tae Ik Chang; Hyun Wook Kim; Jae Hyun Chang; Sun Young Park; Eunyoung Kim; Shin-Wook Kang; Dae-Suk Han; Tae-Hyun Yoo
Journal:  Nephrol Dial Transplant       Date:  2009-06-02       Impact factor: 5.992

10.  Hyperuricemia in childhood primary hypertension.

Authors:  Daniel I Feig; Richard J Johnson
Journal:  Hypertension       Date:  2003-08-04       Impact factor: 10.190

View more
  47 in total

1.  Uricases as therapeutic agents to treat refractory gout: Current states and future directions.

Authors:  Xiaolan Yang; Yonghua Yuan; Chang-Guo Zhan; Fei Liao
Journal:  Drug Dev Res       Date:  2011-12-29       Impact factor: 4.360

2.  Uric acid: the past decade.

Authors:  Diana Rudan; Ozren Polasek; Ivana Kolcić; Igor Rudan
Journal:  Croat Med J       Date:  2010-02       Impact factor: 1.351

3.  Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study.

Authors:  Iddo Z Ben-Dov; Jeremy D Kark
Journal:  Nephrol Dial Transplant       Date:  2011-01-10       Impact factor: 5.992

4.  Efficacy and safety of febuxostat in patients with hyperuricemia and gout.

Authors:  Ignacio Garcia-Valladares; Tahir Khan; Luis R Espinoza
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-10       Impact factor: 5.346

5.  Nephron hypertrophy and glomerulosclerosis and their association with kidney function and risk factors among living kidney donors.

Authors:  Hisham E Elsherbiny; Mariam P Alexander; Walter K Kremers; Walter D Park; Emilio D Poggio; Mikel Prieto; John C Lieske; Andrew D Rule
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-15       Impact factor: 8.237

Review 6.  Secreted klotho and chronic kidney disease.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

7.  Uric acid level and erectile dysfunction in patients with coronary artery disease.

Authors:  Yalcin Solak; Hakan Akilli; Mehmet Kayrak; Alpay Aribas; Abduzhappar Gaipov; Suleyman Turk; Santos E Perez-Pozo; Adrian Covic; Kim McFann; Richard J Johnson; Mehmet Kanbay
Journal:  J Sex Med       Date:  2013-09-25       Impact factor: 3.802

8.  Urine NGAL and KIM-1 in children and adolescents with hyperuricemia.

Authors:  Justyna Tomczak; Anna Wasilewska; Robert Milewski
Journal:  Pediatr Nephrol       Date:  2013-05-15       Impact factor: 3.714

Review 9.  Risk factors for progression of chronic kidney disease.

Authors:  Amy Staples; Craig Wong
Journal:  Curr Opin Pediatr       Date:  2010-04       Impact factor: 2.856

10.  Association of a polymorphism in a gene encoding a urate transporter with CKD progression.

Authors:  Alessandra Testa; Francesca Mallamaci; Belinda Spoto; Anna Pisano; Maria Cristina Sanguedolce; Giovanni Tripepi; Daniela Leonardis; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-17       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.